Sign In
Buy OGI
OrganiGram Holdings Earnings Calls
| Release date | Dec 17, 2025 |
| EPS estimate | -$0.0100 |
| EPS actual | - |
| Revenue estimate | 73.018M |
| Revenue actual | - |
| Expected change | +/- 9.63% |
| Release date | Aug 13, 2025 |
| EPS estimate | -$0.0100 |
| EPS actual | -$0.0470 |
| EPS Surprise | -370.00% |
| Revenue estimate | 73.018M |
| Revenue actual | 70.792M |
| Revenue Surprise | -3.05% |
| Release date | May 12, 2025 |
| EPS estimate | -$0.0400 |
| EPS actual | $0.330 |
| EPS Surprise | 925.00% |
| Revenue estimate | 61.271M |
| Revenue actual | 65.6M |
| Revenue Surprise | 7.06% |
| Release date | Feb 11, 2025 |
| EPS estimate | -$0.0400 |
| EPS actual | -$0.200 |
| EPS Surprise | -400.00% |
| Revenue estimate | 65.27M |
| Revenue actual | 65.6M |
| Revenue Surprise | 0.505% |
Last 4 Quarters for OrganiGram Holdings
Below you can see how OGI.TO performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Feb 11, 2025 |
| Price on release | $2.06 |
| EPS estimate | -$0.0400 |
| EPS actual | -$0.200 |
| EPS surprise | -400.00% |
| Date | Price |
|---|---|
| Feb 05, 2025 | $2.30 |
| Feb 06, 2025 | $2.38 |
| Feb 07, 2025 | $2.38 |
| Feb 10, 2025 | $2.50 |
| Feb 11, 2025 | $2.06 |
| Feb 12, 2025 | $1.92 |
| Feb 13, 2025 | $1.92 |
| Feb 14, 2025 | $1.81 |
| Feb 18, 2025 | $1.93 |
| 4 days before | -10.43% |
| 4 days after | -6.31% |
| On release day | -6.80% |
| Change in period | -16.09% |
| Release date | May 12, 2025 |
| Price on release | $1.80 |
| EPS estimate | -$0.0400 |
| EPS actual | $0.330 |
| EPS surprise | 925.00% |
| Date | Price |
|---|---|
| May 06, 2025 | $1.51 |
| May 07, 2025 | $1.56 |
| May 08, 2025 | $1.55 |
| May 09, 2025 | $1.64 |
| May 12, 2025 | $1.80 |
| May 13, 2025 | $1.72 |
| May 14, 2025 | $1.69 |
| May 15, 2025 | $1.73 |
| May 16, 2025 | $1.87 |
| 4 days before | 19.21% |
| 4 days after | 3.89% |
| On release day | -4.44% |
| Change in period | 23.84% |
| Release date | Aug 13, 2025 |
| Price on release | $2.22 |
| EPS estimate | -$0.0100 |
| EPS actual | -$0.0470 |
| EPS surprise | -370.00% |
| Date | Price |
|---|---|
| Aug 06, 2025 | $1.92 |
| Aug 07, 2025 | $1.94 |
| Aug 08, 2025 | $1.98 |
| Aug 11, 2025 | $2.25 |
| Aug 12, 2025 | $2.22 |
| Aug 14, 2025 | $2.14 |
| Aug 15, 2025 | $2.01 |
| Aug 18, 2025 | $2.12 |
| Aug 19, 2025 | $2.09 |
| 4 days before | 15.63% |
| 4 days after | -5.86% |
| On release day | -3.60% |
| Change in period | 8.85% |
| Release date | Dec 17, 2025 |
| Price on release | - |
| EPS estimate | -$0.0100 |
| EPS actual | - |
| Date | Price |
|---|---|
| Nov 11, 2025 | $2.31 |
| Nov 12, 2025 | $2.25 |
| Nov 13, 2025 | $2.16 |
| Nov 14, 2025 | $2.11 |
| Nov 17, 2025 | $2.12 |
OrganiGram Holdings Earnings Call Transcript Summary of Q2 2025
Organigram reported a record quarter with gross sales up 79% and net revenue up 74% year‑over‑year (Q2 net revenue $65.6M), driven by the first full quarter contribution from the Motif acquisition and stronger international sales. Adjusted gross margin improved to 33% (Organigram standalone 37%) and adjusted EBITDA turned positive at $4.9M for the quarter; management expects margins to stabilize ~35% for fiscal 2025 with a long‑term target of ~40% in H2 FY2026. Management upgraded expected annual run‑rate synergies from Motif to ~$15M (from $10M), with ~$1.5M realized so far this year and ~$5M targeted in the back half of the year. Strategic priorities include international expansion (Germany, UK, Australia and the US hemp‑THC beverage market via Collective Project), EU‑GMP certification to accelerate exports, capacity and extraction investments (LED retrofit, expanded hydrocarbon/distillate capacity, $1.2M beverage line), and deploying remaining Jupiter capital (~$58M) for international M&A/strategic investments. Liquidity remains strong with ~$83.4M cash and negligible debt; management expects to be cash‑flow positive for the fiscal year after seasonal Q3/Q4 strength and plans $8–10M sustaining CapEx plus the Moncton LED program (~$9M).
